Relief Therapeutics Holding AG
RLFTD · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $3 | $6 | $3 | $3 |
| % Growth | -49.2% | 85.4% | -0.4% | – |
| Cost of Goods Sold | $5 | $6 | $8 | $9 |
| Gross Profit | -$2 | -$1 | -$5 | -$6 |
| % Margin | -63.3% | -16.2% | -170.8% | -189.2% |
| R&D Expenses | $1 | $1 | $0 | $1 |
| G&A Expenses | $0 | $0 | $2 | $3 |
| SG&A Expenses | $1 | $2 | $3 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $3 | $6 |
| Operating Income | -$4 | -$4 | -$8 | -$12 |
| % Margin | -127.6% | -72.6% | -274.4% | -385.2% |
| Other Income/Exp. Net | -$12 | $0 | -$39 | -$52 |
| Pre-Tax Income | -$15 | -$4 | -$48 | -$64 |
| Tax Expense | -$3 | $1 | -$6 | -$8 |
| Net Income | -$13 | -$5 | -$42 | -$56 |
| % Margin | -442.9% | -81.7% | -1,384.8% | -1,869% |
| EPS | -1 | -0.36 | -3.32 | -5.1 |
| % Growth | -177.8% | 89.2% | 34.9% | – |
| EPS Diluted | -1 | -0.36 | -3.32 | -5.1 |
| Weighted Avg Shares Out | 13 | 13 | 13 | 11 |
| Weighted Avg Shares Out Dil | 13 | 13 | 13 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $2 | $2 |
| EBITDA | -$14 | -$3 | -$46 | -$62 |
| % Margin | -501% | -45.1% | -1,523.4% | -2,062.5% |